Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.57 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028030 | 1.00 | FSCN1 (0.57) | FSCN1HCRTR2KMT2APYGMMEN1 | |
| SCHEMBL30501135 | 0.90 | FSCN1 (0.58) | FSCN1KMT2APYGMHDAC3HDAC1 | |
| SCHEMBL17038764 | 0.90 | FSCN1 (0.58) | FSCN1KMT2APYGMMEN1HSD17B10 | |
| SCHEMBL30501122 | 0.90 | FSCN1 (0.58) | FSCN1KMT2APYGMMEN1HSD17B10 | |
| SCHEMBL17199346 | 0.90 | FSCN1 (0.58) | FSCN1HCRTR2KMT2APYGMMEN1 | |
| SCHEMBL17038745 | 0.90 | FSCN1 (0.58) | FSCN1KMT2APYGMHDAC3HDAC1 | |
| SCHEMBL17038867 | 0.88 | FSCN1 (0.75) | FSCN1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL30695053 | 0.88 | FSCN1 (0.75) | FSCN1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL17038924 | 0.87 | FSCN1 (0.55) | FSCN1KMT2APYGMNPSR1HDAC3 | |
| SCHEMBL30694999 | 0.87 | FSCN1 (0.55) | FSCN1KMT2APYGMNPSR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | NOVITA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2025-10-30 | — | — | US | disclosed |
| US-12168658-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885HCRTR2 3383/4885KMT2A 4757/4885 |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | PDCD1, CD274, PDCD4 | FSCN1 936/4885HCRTR2 3760/4885KMT2A 2544/4885 |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885HCRTR2 3383/4885KMT2A 4757/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | FSCN1 1/4885HCRTR2 3383/4885KMT2A 4757/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | FSCN1 1017/4885HCRTR2 2923/4885KMT2A 1480/4885 |
| US-12168658-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | FSCN1 1/4885HCRTR2 3383/4885KMT2A 4757/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | FSCN1 1017/4885HCRTR2 2923/4885KMT2A 1480/4885 |
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CCR10, CCR4, OGFR | FSCN1 3152/4885HCRTR2 33/4885KMT2A 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.